Novartis AG
Novartis AG (NVS): 405 pipeline candidates · 90 upcoming catalysts · 407 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E 1.38 · 0% dilution
Lead: Phase 3
405 candidates
90 upcoming, next in ~5d
N/A
A transparent, data-derived signal for Novartis AGacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$293.7B
Cash
$2.6B
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (405 candidates)
| Drug | Phase |
|---|---|
| [177lu]lu-dota-tate | Phase 1/Phase 2 |
| [177Lu]Lu-DOTA-TATE | Phase 3 |
| [177Lu]Lu-DOTATATE | Phase 2 |
| [177lu]lu-neob | Phase 1/Phase 2 |
| [177lu]lu-neob | Phase 4 |
| [177lu]lu-nns309 | Phase 1 |
| [177lu]lu-nns309 | Phase 1/Phase 2 |
| [177lu]lu-psma-617 | Phase 1 |
| [177Lu]Lu-PSMA-617 | Phase 1 |
| [18f]ctt1057 | Phase 2/Phase 3 |
Showing 10 of 405 candidates. Sign up for full pipeline.
Upcoming Catalysts (90)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,588
Total value held
$19.39B
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 8,527,037 | $1.30B |
| dimensional fund advisors lp | 8,110,116 | $1.24B |
| primecap management co/ca/ | 7,567,354 | $1.16B |
| dodge & cox | 6,967,383 | $1.06B |
| goldman sachs group inc | 6,525,771 | $996.8M |
| bank of america corp /de/ | 4,962,794 | $758.1M |
| janus henderson group plc | 4,551,876 | $695.3M |
| franklin resources inc | 3,409,944 | $520.9M |
| blackrock, inc. | 2,949,760 | $450.6M |
| northern trust corp | 2,786,228 | $425.6M |
Showing top 10 of 1,588 institutional holders of Novartis AG. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Novartis AG's pipeline?
Novartis AG (NVS) has 405 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Novartis AG's lead drug candidate?
Novartis AG's most advanced tracked candidate is [177lu]lu-dota-tate (Phase 1/Phase 2) for Metastatic Neuroendocrine Prostate Cancer; Glioblastoma; Extensive Stage Small Cell Lung Cancer.
What is Novartis AG's next catalyst?
Novartis AG's next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1b, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Study to Evaluate" — expected June 23, 2026.
What is Novartis AG's market capitalization?
Novartis AG's market capitalization is approximately $293.7B.
Who is the CEO of Novartis AG?
Dr. Vasant Narasimhan M.D. is the chief executive officer of Novartis AG (NVS).
Get the full picture on Novartis AG
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.